EphB4 promotes or suppresses Ras/MEK/ERK pathway in a context-dependent manner: Implications for EphB4 as a cancer target

Cancer Biology and Therapy

Volumn 13, Issue 8, 2012, Pages 631-638

  Xiao, Zhan ^a   Carrasco, Rosa A ^a   Kinneer, Krista ^a   Sabol, Darrin ^a   Jallal, Bahija ^a   Coats, Steve ^a   Tice, David A ^a  

^a MEDIMMUNE   (United States)

Author keywords

EphB4; EphrinB2; ERK; P120 EasGAP; PP2A

Indexed keywords

EPHRIN RECEPTOR; EPHRIN RECEPTOR B4; GLYCOPROTEIN GP 120; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN TYROSINE KINASE; RAS PROTEIN; SMALL INTERFERING RNA; VASCULOTROPIN; EPHRIN B2; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN P21;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER THERAPY; CELL COMPARTMENTALIZATION; CELL PROLIFERATION; ENDOTHELIUM CELL; FLUORESCENCE ACTIVATED CELL SORTER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; ONCOGENE; UMBILICAL VEIN ENDOTHELIAL CELL; VIRUS ONCOGENE; AGONISTS; DRUG EFFECTS; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; NEOPLASM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL PROLIFERATION; EPHRIN-B2; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPHB4;

EID: 84884283340     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.13.8.20080     Document Type: Article

References (28)

1. Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell 2008; 133:38-52; http://dx.doi.org/10.1016/j.cell.2008.03.011; PMID:18394988.
2. Egea J, Klein R. Bidirectional Eph-ephrin signaling during axon guidance. Trends Cell Biol 2007; 17:230-8; http://dx.doi.org/10.1016/j.tcb.2007.03.004; PMID:17420126.
3. Himanen JP, Saha N, Nikolov DB. Cell-cell signaling via Eph receptors and ephrins. Curr Opin Cell Biol 2007; 19:534-42; http://dx.doi.org/10.1016/j.ceb. 2007.08.004; PMID:17928214.
4. Gerety SS, Wang HU, Chen ZF, Anderson DJ. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 1999; 4:403-14; http://dx.doi.org/10.1016/ S1097-2765(00)80342-1; PMID:10518221.
5. Füller T, Korff T, Kilian A, Dandekar G, Augustin HG. Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells. J Cell Sci 2003; 116:2461-70; http://dx.doi.org/10. 1242/jcs.00426; PMID:12734395.
6. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010; 10:165-80; http://dx.doi.org/10. 1038/nrc2806; PMID:20179713.
7. Noren NK, Foos G, Hauser CA, Pasquale EB. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol 2006; 8:815-25; http://dx.doi.org/10.1038/ncb1438; PMID:16862147.
8. Kuang SQ, Bai H, Fang ZH, Lopez G, Yang H, Tong W, et al. Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia. Blood 2010; 115:2412-9; http://dx.doi.org/10.1182/blood-2009-05-222208; PMID:20061560.
9. Clevers H, Batlle E. EphB/EphrinB receptors and Wnt signaling in colorectal cancer. Cancer Res 2006; 66:2-5; http://dx.doi.org/10.1158/0008-5472. CAN-05-3849; PMID:16397205.
10. Cortina C, Palomo-Ponce S, Iglesias M, Fernández-Masip JL, Vivancos A, Whissell G, et al. EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Nat Genet 2007; 39:1376-83; http://dx.doi.org/10.1038/ng.2007.11; PMID:17906625.
11. Davalos V, Dopeso H, Castaño J, Wilson AJ, Vilardell F, Romero-Gimenez J, et al. EPHB4 and survival of colorectal cancer patients. Cancer Res 2006; 66:8943-8; http://dx.doi.org/10.1158/0008-5472.CAN-05-4640; PMID:16982731.
12. Batlle E, Bacani J, Begthel H, Jonkheer S, Gregorieff A, van de Born M, et al. EphB receptor activity suppresses colorectal cancer progression. Nature 2005; 435:1126-30; http://dx.doi.org/10.1038/nature03626; PMID:15973414.
13. Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, et al. The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer 2007; 96:1083-91; http://dx.doi.org/10.1038/sj.bjc.6603642; PMID:17353927.
14. Kumar SR, Scehnet JS, Ley EJ, Singh J, Krasnoperov V, Liu R, et al. Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. Cancer Res 2009; 69:3736-45; http://dx.doi.org/10.1158/0008- 5472.CAN-08-3232; PMID:19366806.
15. Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, et al. EphB4 expression and biological significance in prostate cancer. Cancer Res 2005; 65:4623-32; http://dx.doi.org/10.1158/0008-5472.CAN-04-2667; PMID:15930280.
16. Martiny-Baron G, Korff T, Schaffner F, Esser N, Eggstein S, Marmé D, et al. Inhibition of tumor growth and angiogenesis by soluble EphB4. Neoplasia 2004; 6:248-57; http://dx.doi.org/10.1593/neo.03457; PMID:15153337.
17. Kertesz N, Krasnoperov V, Reddy R, Leshanski L, Kumar SR, Zozulya S, et al. The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis and inhibits tumor growth. Blood 2006; 107:2330-8; http://dx.doi.org/10.1182/blood-2005-04-1655; PMID:16322467.
18. Kim I, Ryu YS, Kwak HJ, Ahn SY, Oh JL, Yancopoulos GD, et al. EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin 1-induced Ras/mitogen-activated protein kinase pathway in venous endothelial cells. FASEB J 2002; 16:1126-8; http://dx.doi.org/10.1096/fj.01-0805fje; PMID:12039842.
19. Elowe S, Holland SJ, Kulkarni S, Pawson T. Downregulation of the Ras-mitogen-activated protein kinase pathway by the EphB2 receptor tyrosine kinase is required for ephrin-induced neurite retraction. Mol Cell Biol 2001; 21:7429-41; http://dx.doi.org/10.1128/MCB.21.21.7429-41.2001; PMID:11585923.
20. Parri M, Buricchi F, Taddei ML, Giannoni E, Raugei G, Ramponi G, et al. EphrinA1 repulsive response is regulated by an EphA2 tyrosine phosphatase. J Biol Chem 2005; 280:34008-18; http://dx.doi.org/10.1074/jbc.M502879200; PMID:16051609.
21. Miao H, Burnett E, Kinch M, Simon E, Wang B. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation Nat Cell Biol 2000; 2:62-9; http://dx.doi.org/10.1038/35000008; PMID:10655584.
22. Noren NK, Pasquale EB. Paradoxes of the EphB4 receptor in cancer. Cancer Res 2007; 67:3994-7; http://dx.doi.org/10.1158/0008-5472.CAN-07-0525; PMID:17483308.
23. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 2001; 353:417-39; PMID:11171037; http://dx.doi.org/10.1042/0264-6021:3530417.
24. Van Kanegan MJ, Adams DG, Wadzinski BE, Strack S. Distinct protein phosphatase 2A heterotrimers modulate growth factor signaling to extracellular signal-regulated kinases and Akt. J Biol Chem 2005; 280:36029-36; http://dx.doi.org/10.1074/jbc.M506986200; PMID:16129692.
25. Hu X, Wu X, Xu J, Zhou J, Han X, Guo J. Src kinase upregulates the ERK cascade through inactivation of protein phosphatase 2A following cerebral ischemia. BMC Neurosci 2009; 10:74; http://dx.doi.org/10.1186/1471-2202-10-74; PMID:19602257.
26. Adams DG, Coffee RL Jr, Zhang H, Pelech S, Strack S, Wadzinski BE. Positive regulation of Raf1-MEK1/2-ERK1/2 signaling by protein serine/threonine phosphatase 2A holoenzymes. J Biol Chem 2005; 280:42644-54; http://dx.doi.org/ 10.1074/jbc.M502464200; PMID:16239230.
27. Ory S, Zhou M, Conrads TP, Veenstra TD, Morrison DK. Protein phosphatase 2A positively regulates Ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites. Curr Biol 2003; 13:1356-64; http://dx.doi.org/10. 1016/S0960-9822(03)00535-9; PMID:12932319.
28. Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley EJ, et al. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol 2006; 169:279-93; http://dx.doi.org/10.2353/ajpath.2006.050889; PMID:16816380.